CA3142019A1 - Novel crispr dna targeting enzymes and systems - Google Patents

Novel crispr dna targeting enzymes and systems Download PDF

Info

Publication number
CA3142019A1
CA3142019A1 CA3142019A CA3142019A CA3142019A1 CA 3142019 A1 CA3142019 A1 CA 3142019A1 CA 3142019 A CA3142019 A CA 3142019A CA 3142019 A CA3142019 A CA 3142019A CA 3142019 A1 CA3142019 A1 CA 3142019A1
Authority
CA
Canada
Prior art keywords
crispr
nucleic acid
seq
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3142019A
Other languages
English (en)
French (fr)
Inventor
David A. Scott
David R. Cheng
Winston X. YAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbor Biotechnologies Inc
Original Assignee
Arbor Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Biotechnologies Inc filed Critical Arbor Biotechnologies Inc
Publication of CA3142019A1 publication Critical patent/CA3142019A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3142019A 2019-06-14 2020-06-12 Novel crispr dna targeting enzymes and systems Pending CA3142019A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962861582P 2019-06-14 2019-06-14
US62/861,582 2019-06-14
US201962872157P 2019-07-09 2019-07-09
US62/872,157 2019-07-09
US201962873602P 2019-07-12 2019-07-12
US201962873606P 2019-07-12 2019-07-12
US62/873,602 2019-07-12
US62/873,606 2019-07-12
PCT/US2020/037585 WO2020252378A1 (en) 2019-06-14 2020-06-12 Novel crispr dna targeting enzymes and systems

Publications (1)

Publication Number Publication Date
CA3142019A1 true CA3142019A1 (en) 2020-12-17

Family

ID=73781310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3142019A Pending CA3142019A1 (en) 2019-06-14 2020-06-12 Novel crispr dna targeting enzymes and systems

Country Status (7)

Country Link
US (1) US20220315913A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983536A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538789A (cg-RX-API-DMAC7.html)
CN (1) CN114269912A (cg-RX-API-DMAC7.html)
AU (1) AU2020291467A1 (cg-RX-API-DMAC7.html)
CA (1) CA3142019A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025588A4 (en) * 2019-09-05 2023-09-06 Arbor Biotechnologies, Inc. NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
US20240093228A1 (en) * 2021-01-22 2024-03-21 Arbor Biotechnologies, Inc. Compositions comprising a nuclease and uses thereof
AU2022284804A1 (en) 2021-06-01 2023-12-07 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
US20260232844A1 (en) 2023-02-15 2026-08-13 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2025201481A1 (en) * 2024-03-29 2025-10-02 Yoltech Therapeutics Co., Ltd Crispr-cas systems
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074199B1 (en) * 2013-11-19 2015-07-07 President And Fellows Of Harvard College Mutant Cas9 proteins
WO2017044776A1 (en) * 2015-09-10 2017-03-16 Texas Tech University System Single-guide rna (sgrna) with improved knockout efficiency
CN109688820B (zh) * 2016-06-24 2023-01-10 科罗拉多州立大学董事会(法人团体) 用于生成条形码化组合文库的方法
AU2017388379A1 (en) * 2016-12-28 2019-06-06 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and uses thereof
US9982279B1 (en) * 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
WO2019051419A1 (en) * 2017-09-08 2019-03-14 University Of North Texas Health Science Center Engineered cas9 variants
US20200255829A1 (en) * 2017-11-02 2020-08-13 Arbor Biotechnologies, Inc. Novel crispr-associated transposon systems and components

Also Published As

Publication number Publication date
EP3983536A4 (en) 2023-11-29
JP2022538789A (ja) 2022-09-06
EP3983536A1 (en) 2022-04-20
AU2020291467A1 (en) 2021-12-23
US20220315913A1 (en) 2022-10-06
CN114269912A (zh) 2022-04-01
WO2020252378A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
CA3150454A1 (en) Novel crispr dna targeting enzymes and systems
AU2022204298B2 (en) Nucleobase editors and uses thereof
US11667904B2 (en) CRISPR-associated systems and components
US11643654B2 (en) Crispr DNA targeting enzymes and systems
US20220098579A1 (en) Novel crispr dna targeting enzymes and systems
US20220133790A1 (en) Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance
CA3081346A1 (en) Novel crispr-associated transposon systems and components
AU2025217267A1 (en) Novel CRISPR DNA and RNA targeting enzymes and systems
CA3153005A1 (en) Novel crispr dna targeting enzymes and systems
US20230016656A1 (en) Novel crispr dna targeting enzymes and systems
US20220315913A1 (en) Novel crispr dna targeting enzymes and systems
CA3141721A1 (en) Novel crispr dna targeting enzymes and systems
US20260085330A1 (en) Karyocreate (karyotype crispr engineered aneuploidy technology)

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260703